{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:10:37Z","timestamp":1772165437983,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Emerg Med"],"DOI":"10.1186\/s12245-025-00963-8","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:03:42Z","timestamp":1755036222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Oph\u00e9lie","family":"Dirand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Lamamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"963_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108625","author":"T-H Shen","year":"2023","unstructured":"Shen T-H,et, Joel F. \u00ab utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: findings from NHANES 2013\u20132020 \u00bb. J Diabetes Complicat. 2023. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108625.","journal-title":"J Diabetes Complicat"},{"key":"963_CR2","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D. etal. 2022AHA\/ACC\/HFSAGuideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u2013e1032.\u00a0https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"16","key":"963_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, EMPEROR-Preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"4","key":"963_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"issue":"22","key":"963_CR5","doi-asserted-by":"publisher","first-page":"211728","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,etal. \u00ab empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes \u00bb. N Engl J Med. 2015;373(22):211728. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"5","key":"963_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2024.10510","volume":"332","author":"CAM Tavares","year":"2024","unstructured":"Tavares CAM, Azevedo LCP, Rea-Neto \u00c1. Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. 2024;332(5):401\u201311. https:\/\/doi.org\/10.1001\/jama.2024.10510.","journal-title":"JAMA"},{"key":"963_CR7","unstructured":"de Velasco G. Mar\u00eda Isabel S\u00e1nchez-Molina acosta, et Mar\u00eda matilde Toval fern\u00e1ndez. 2021. \u00ab diabetic euglycemic ketoacidosis induced by oral antidiabetics type SGLT2i \u00bb. EJIFCC32(1):10510."},{"key":"963_CR8","doi-asserted-by":"publisher","unstructured":"Diaz-Ramos A, Eilbert W, etDiego Marquez. 2019.\u00abEuglycemicdiabickoacidosisassociatedwithsodium-glucosecotransporter-2inhibitoruse:acasereportandreviewoftheliterature\u00bb.International Journal of Emergency Medicine12(septembre):27.https:\/\/doi.org\/10.1186\/s12245-019-0240-0","DOI":"10.1186\/s12245-019-0240-0"},{"issue":"12","key":"963_CR9","doi-asserted-by":"publisher","first-page":"e75399","DOI":"10.7759\/cureus.75399","volume":"16","author":"A Hedary","year":"2024","unstructured":"Hedary A, Melder L, Micah Pippin. \u00ab A case of euglycemic diabetic ketoacidosis associated with a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor \u00bb. Cureus. 2024;16(12):e75399. https:\/\/doi.org\/10.7759\/cureus.75399.","journal-title":"Cureus"},{"issue":"4","key":"963_CR10","doi-asserted-by":"publisher","first-page":"e4496","DOI":"10.7759\/cureus.4496","volume":"11","author":"F Bteich","year":"2019","unstructured":"Bteich F, Daher G, Kapoor A, Charbek E, Kamel G. Post-surgical euglycemic diabetic ketoacidosis in a patient on empagliflozin in the intensive care unit. Cureus. 2019;11(4):e4496. https:\/\/doi.org\/10.7759\/cureus.4496. Published 2019 Apr 18.","journal-title":"Cureus"},{"issue":"2","key":"963_CR11","doi-asserted-by":"publisher","first-page":"21626","DOI":"10.1111\/fcp.12334","volume":"32","author":"A AdoMoumouni","year":"2018","unstructured":"AdoMoumouni A. \u00ab SGLT-2 inhibitors and ketoacidosis: A disproportionality analysis in the world health organization\u2019s adverse drug reactions database \u00bb. Fundam Clin Pharmacol. 2018;32(2):21626. https:\/\/doi.org\/10.1111\/fcp.12334.","journal-title":"Fundam Clin Pharmacol"},{"key":"963_CR12","doi-asserted-by":"publisher","unstructured":"Wysham C, Bindal A, Levrat-Guillen F, Kostadinova D, etYeesha Poon. 2025.\u00abASystematicLiteratureReviewontheBurdenofDiabicKoacidosisinType2DiabesMellitus\u00bb.Diabes,Obesity&Mabolism,mars.https:\/\/doi.org\/10.1111\/dom.16282","DOI":"10.1111\/dom.16282"},{"key":"963_CR13","doi-asserted-by":"publisher","unstructured":"Schutte B, Savage K, Merwin M, Morris M, Geringer R, Dilsaver DB, Plambeck RW, etNikhil Jagan. 2025 \u00ab euglycemic diabic koacidosis: rising incidence, diagnostic delays, and the impact of SGLT2 inhibitors in hospitalized patients \u00bb. J Hosp Med.https:\/\/doi.org\/10.1002\/jhm.70015","DOI":"10.1002\/jhm.70015"},{"key":"963_CR14","doi-asserted-by":"publisher","first-page":"bcr2013201554","DOI":"10.1136\/bcr-2013-201554","volume":"2013","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013:bcr2013201554. https:\/\/doi.org\/10.1136\/bcr-2013-201554. Published 2013 Oct 23.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"963_CR15","first-page":"337","volume":"87","author":"DP Westerberg","year":"2013","unstructured":"Westerberg DP. Diabetic ketoacidosis: evaluation and treatment. Am Fam Physician. 2013;87(5):337\u201346.","journal-title":"Am Fam Physician"},{"issue":"2","key":"963_CR16","doi-asserted-by":"publisher","first-page":"13538","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Kazuhiko Sakaguchi. \u00ab euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors \u00bb. J Diabetes Invest. 2016;7(2):13538. https:\/\/doi.org\/10.1111\/jdi.12401.","journal-title":"J Diabetes Invest"},{"issue":"8","key":"963_CR17","doi-asserted-by":"publisher","first-page":"128491","DOI":"10.2215\/CJN.17621120","volume":"16","author":"BF Palmer","year":"2021","unstructured":"Palmer BF,et, Deborah J. \u00ab euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy \u00bb. Clin J Am Soc Nephrology: CJASN. 2021;16(8):128491. https:\/\/doi.org\/10.2215\/CJN.17621120.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"963_CR18","doi-asserted-by":"publisher","unstructured":"Malherbe J. DamienduCheyron,etXavierValette.2025.\u00abUnderstandingtheDisease:EuglycemicKetoacidosiswithSGLT2Inhibitors\u00bb.IntensiveCareMedicine.https:\/\/doi.org\/10.1007\/s00134-025-07806-3","DOI":"10.1007\/s00134-025-07806-3"},{"issue":"5","key":"963_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00228-020-03051-3","volume":"77","author":"A Bamgboye","year":"2021","unstructured":"Bamgboye A, Collier Andrew. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. 2021;77(5):651\u20137. https:\/\/doi.org\/10.1007\/s00228-020-03051-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"963_CR20","doi-asserted-by":"publisher","first-page":"14345","DOI":"10.1007\/s00134-024-07704-0","volume":"51","author":"B Garcia","year":"2025","unstructured":"Garcia B, Ostermann M, Matthieu Legrand. \u00ab how to manage Sodium-Glucose Cotransporter-2 inhibitors in the critically ill patient?? \u00bb. Intensive Care Med. 2025;51(1):14345. https:\/\/doi.org\/10.1007\/s00134-024-07704-0.","journal-title":"Intensive Care Med"},{"issue":"12","key":"963_CR21","first-page":"2027","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM. SGLT2 Inhibitors. Physiol Pharmacol Kidney360. 2021;2(12):2027\u201337.","journal-title":"Physiol Pharmacol Kidney360"}],"container-title":["International Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12245-025-00963-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12245-025-00963-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12245-025-00963-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:03:43Z","timestamp":1755036223000},"score":1,"resource":{"primary":{"URL":"https:\/\/intjem.biomedcentral.com\/articles\/10.1186\/s12245-025-00963-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1186\/s12245-025-00963-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6937408\/v1","asserted-by":"object"}]},"ISSN":["1865-1380"],"issn-type":[{"value":"1865-1380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Written informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A consent for publication is obtained from the patient\u2019s family, as the patient was unable to provide consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}